Companies /Healthcare

Natera Inc

NASDAQ: NTRA Diagnostics & Research
$316.21
▼ $6.73 (−2.08%) today
Markets open · 12:40pm ET

24/7 Wall St. View

Price Prediction $467.42 +44.7% Our analysts’ 12-month view: target, optimistic case, and floor. NTRA price prediction → Earnings Miss −49.8% EPS vs. the estimate, revenue, and how the market reacted. NTRA earnings history →

NTRA at a Glance

Valuation
Market cap
$46.4B
Profitability
Revenue (TTM)
$2.9B
Profit margin
-5.7%
EPS (TTM)
$-1.12
Price
52-week range
$181 – $437
24/7 target
$467.42
Street target
$410.02
Earnings
Q3 2026 EPS
$-0.42
vs. $-0.28 est.
−49.8%

Headquartered in Austin, TX Fiscal year ends December NASDAQ: NTRA natera.com

About Natera

Natera, Inc. is a diagnostics company focused on cell-free DNA and precision medicine across oncology, women's health and organ health. It generates revenue mainly from product (testing) revenues, with smaller licensing and other revenues. Key products include:
- **Signatera:** a tumor-informed molecular residual disease (MRD) test for cancer recurrence monitoring. It now has Medicare coverage in several indications, including early-stage hepatocellular carcinoma, and PMDA approvals in Japan for colorectal cancer and as a companion diagnostic in muscle-invasive bladder cancer. Next-generation versions include Signatera Genome with Phased and Structural Variants.
- **Latitude:** an MRD test.
- **Panorama:** a prenatal screening test.

Natera also runs a growing pharma business that provides testing, clinical trial services and data licensing for oncology and organ health trials. It is developing early cancer detection products, including a colorectal cancer screening test (FIND-CRC study) and a multi-cancer early detection assay with FDA Breakthrough Device Designation. The company operates CLIA-certified, CAP-accredited and ISO 13485-certified laboratories in Austin, Texas, San Carlos, California, and Boulder, Colorado. Its tests are supported by more than 400 peer-reviewed publications. Updated

Revenue by Segment · Q3 2026
  1. Product Revenues99%
  2. Licensing and Other Revenues1%

Latest Activity

Biggest movers · On the open
Gainers
  • IRENIREN$20.35+11.3%
  • LRCXLam Research$201.97+9.3%
  • ABNBAirbnb$186.18+9.2%
  • AMDAMD$435.85+7.9%
  • KLACKLA$138.1+7.6%
Losers
  • DKNGDraftKings$16.63-29.0%
  • AXONAxon Enterprise$311.65-18.8%
  • NTRANatera$307.66-15.4%
  • LYFTLyft$16.46-7.9%
  • OPENOpendoor Technologies$1.66-6.7%

DraftKings opened down nearly 29% at $16.63, a 40-point gap between it and the day's top gainer across our 379-stock board. Semis and travel took the other side, with Lam Research, Airbnb and AMD all up 8% or more.

Read more
NTRANatera
After-hours
$380.71
-8.40%open $415.64

An 8.4% slide to $380.71 takes roughly $5 billion off Natera's $54.9 billion market cap in a single session. Moves this big are rare for a name this size, so watch whether the $415 open gets reclaimed.

Read more
NTRANatera
Regular session
$388.82
-6.45%open $415.64

A 6.45% slide to $388.82 strips roughly $3.6 billion off Natera's $56 billion market value in a single session. Whether the stock holds the $388 area into the close is the level to keep an eye on.

Read more
NTRANatera
New 52-week high$436+2.4% vs prior high · 2026-10-05

Natera just set a fresh 52-week high at $436, more than double its $182 low a year ago.

Read more
NTRANatera
Regular session
$400.62
-6.62%open $429.01

A 6.62% slide to $400.62 strips close to $4 billion off a $57.7 billion genetic testing name in a single session. The $429 open is now the level to beat back.

Read more
NTRANatera
Regular session
$400.94
-6.54%open $429.01

A 6.5% slide to $400.94 strips roughly $4 billion off a $57.8 billion diagnostics name in a single session. The $400 level is the line to watch from here.

Read more
NTRANatera
New 52-week high$425.64+2.7% vs prior high · 2026-09-29

Natera notched a fresh 52-week high at $425.64, topping its September 29 peak. Each new high is getting harder to ignore.

Read more

NTRA Coverage

11:53am ET
Investing

TWST vs. NTRA: Which Genomics Play Is a Better Buy?

Cathie Wood’s Ark funds have been really heating up in recent months. Perhaps her most intriguing and underrated fund is the Ark Genomics Revolution ETF (ARKG), which is packed full of extraordinary…

NTRA TWST
Joey Frenette

Frequently Asked Questions

What does Natera do?

Natera, Inc. is a diagnostics company focused on cell-free DNA and precision medicine across oncology, women's health and organ health. It generates revenue mainly from product (testing) revenues, with smaller licensing and other revenues.

What is the NTRA stock price target?

24/7 Wall St.'s 12-month price target for NTRA is $467.42, rated Buy. The Wall Street consensus target is $410.02. NTRA price prediction →